학술논문
Outcomes of fecal carriage of extended-spectrum β-lactamase after transrectal ultrasound-guided biopsy of the prostate.
Document Type
Academic Journal
Author
Tukenmez Tigen E; Department of Infectious Diseases, School of Medicine, Marmara University, Istanbul, Turkey. Electronic address: drzafer@gmail.com.; Tandogdu Z; Department of Urology, Taksim Training and Research Hospital, Istanbul, Turkey.; Ergonul O; Department of Infectious Diseases, School of Medicine, Koç University, Istanbul, Turkey.; Altinkanat G; Department of Infectious Diseases, School of Medicine, Marmara University, Istanbul, Turkey.; Gunaydin B; Department of Urology, Goztepe Training and Research Hospital, Istanbul, Turkey.; Ozgen M; Department of Urology, Marmara University, Istanbul, Turkey.; Sariguzel N; Department of Infectious Diseases, Acibadem Hospital, Istanbul, Turkey.; Erturk Sengel B; Department of Infectious Diseases, School of Medicine, Marmara University, Istanbul, Turkey.; Odabasi Z; Department of Infectious Diseases, School of Medicine, Marmara University, Istanbul, Turkey.; Cek M; Department of Urology, School of Medicine, Trakya University, Edirne, Turkey.; Tokuc R; Department of Urology, Goztepe Training and Research Hospital, Istanbul, Turkey.; Turkeri L; Department of Urology, Marmara University, Istanbul, Turkey.; Mulazimoglu L; Department of Infectious Diseases, School of Medicine, Marmara University, Istanbul, Turkey.; Korten V; Department of Infectious Diseases, School of Medicine, Marmara University, Istanbul, Turkey.
Source
Publisher: Elsevier Science Country of Publication: United States NLM ID: 0366151 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-9995 (Electronic) Linking ISSN: 00904295 NLM ISO Abbreviation: Urology Subsets: MEDLINE
Subject
Language
English
Abstract
Objective: To determine the prevalence of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae (PE) fecal carriage in patients that undergo transrectal ultrasonography-guided biopsy (TRUSbx) and its relationship with post-biopsy infections.
Methods: A prospective clinical study in 4 different tertiary hospitals between 2008 and 2010 was conducted. Four hundred men with sterile urine who were to undergo a TRUSbx because of the suspicion of prostate cancer were included and followed for 14 days after biopsy. Rectal swab culture specimens were acquired immediately before the procedure. Demographic data, prophylaxis choice, quinolone or any other antibiotic consumption within the past 2 months, history of prostatitis, repeat biopsy, intensive care unit admission, hospitalization, urethral catheterization, diabetes mellitus (DM), and steroid usage were recorded.
Results: ESBL carriage was detected in 19% of patients and quinolone use within the last 2 months; other antibiotic use within the last 2 months and DM were found to be significantly associated (P <.05). Symptomatic urinary tract infection (UTI) on the third day after biopsy was seen in 9% of patients and was associated with fluoroquinolone (FQ) consumption before biopsy. Although ESBL-PE carriage was associated with post-biopsy UTI symptoms, it was not found to be associated with post-biopsy symptomatic UTI. Urosepsis was seen in 2 patients (0.5%) after biopsy, and both the patients were ESBL-PE carriers.
Conclusion: The presence of ESBL-PE was associated with DM and FQ consumption before biopsy. ESBL-PE carriage was associated with a high rate of post-biopsy UTI symptoms requiring further elucidation; however, it was not associated with microbiologically proven infections. FQ consumption before TRUSbx was also associated with post-biopsy infections.
(Copyright © 2014 Elsevier Inc. All rights reserved.)
Methods: A prospective clinical study in 4 different tertiary hospitals between 2008 and 2010 was conducted. Four hundred men with sterile urine who were to undergo a TRUSbx because of the suspicion of prostate cancer were included and followed for 14 days after biopsy. Rectal swab culture specimens were acquired immediately before the procedure. Demographic data, prophylaxis choice, quinolone or any other antibiotic consumption within the past 2 months, history of prostatitis, repeat biopsy, intensive care unit admission, hospitalization, urethral catheterization, diabetes mellitus (DM), and steroid usage were recorded.
Results: ESBL carriage was detected in 19% of patients and quinolone use within the last 2 months; other antibiotic use within the last 2 months and DM were found to be significantly associated (P <.05). Symptomatic urinary tract infection (UTI) on the third day after biopsy was seen in 9% of patients and was associated with fluoroquinolone (FQ) consumption before biopsy. Although ESBL-PE carriage was associated with post-biopsy UTI symptoms, it was not found to be associated with post-biopsy symptomatic UTI. Urosepsis was seen in 2 patients (0.5%) after biopsy, and both the patients were ESBL-PE carriers.
Conclusion: The presence of ESBL-PE was associated with DM and FQ consumption before biopsy. ESBL-PE carriage was associated with a high rate of post-biopsy UTI symptoms requiring further elucidation; however, it was not associated with microbiologically proven infections. FQ consumption before TRUSbx was also associated with post-biopsy infections.
(Copyright © 2014 Elsevier Inc. All rights reserved.)